Posted by Michael Wonder on 06 Oct 2016
AbbVie's new oral therapy Venclexta now available for Canadians with a difficult-to-treat blood cancer
5 October 2016 - Health Canada's approval of Venclexta reinforces AbbVie's growing position in hematologic oncology.
AbbVie today announced Health Canada has issued a notice of compliance with conditions (NOC/c) for Venclexta (venetoclax). The therapy has been approved for previously treated chronic lymphocytic leukaemia patients, who have either a genetic mutation, known as 17p deletion, or no other available treatment options.
Under NOC/c policy, AbbVie will provide Health Canada with data from additional studies to confirm the clinical benefit of Venclexta.
